This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2009 by Steno Diabetes Center.
Recruitment status was:  Not yet recruiting
Sponsor:
Information provided by:
Steno Diabetes Center
ClinicalTrials.gov Identifier:
NCT00843388
First received: February 12, 2009
Last updated: NA
Last verified: January 2009
History: No changes posted
  Purpose
A double blind, randomized, cross over study in type 1 diabetic patients. 20 patients, age 18-65 years is treated with spironolacton (Hexalacton (R)) for 60 days followed by 60 days treatment with placebo(or opposite). Primary aim: albuminuria, an expected decrease during hexalacton treatment. Secondary aim: ambulatory blood pressure, GFR, plasma-renin, angiotensin, aldosteron.

Condition Intervention Phase
Diabetes Mellitus Nephropathy Blood Pressure Drug: Spironolacton (hexalacton(R)) Drug: placebo tablet Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Doubleblind Placebo Controlled Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria

Resource links provided by NLM:


Further study details as provided by Steno Diabetes Center:

Primary Outcome Measures:
  • albuminuria, expected decrease [ Time Frame: 60 days ]

Secondary Outcome Measures:
  • GFR [ Time Frame: 60 days ]
  • ambulatory blood pressure [ Time Frame: 60 days ]
  • plasma renin, angiotensin, aldosteron [ Time Frame: 60 days ]

Estimated Enrollment: 20
Study Start Date: March 2009
Estimated Study Completion Date: March 2010
Estimated Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
60 days treatment with tablet hexalacton 25 mg OD.
Drug: Spironolacton (hexalacton(R))
Tablet Spironolacton 25 mg OD
Placebo Comparator: 2
Inactive drug of 25 mg OD
Drug: placebo tablet
placebo tablet 25 mg OD

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • type 1 diabetes
  • age 18-80 years
  • microalbuminuria

Exclusion Criteria:

  • blood pressure> 160/100 mmHg
  • persistent macroalbuminuria
  • pregnancy or in risc of this
  • P-Potassium>5.7 mmol/l
  • Eplerone treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00843388

Sponsors and Collaborators
Steno Diabetes Center
Investigators
Principal Investigator: stine e nielsen, MD Steno Diabetes Center
  More Information

Responsible Party: Peter Rossing, Steno Diabetes Center, Dep 520
ClinicalTrials.gov Identifier: NCT00843388     History of Changes
Other Study ID Numbers: 2306
Eudra CT: 2008-004839-38
Study First Received: February 12, 2009
Last Updated: February 12, 2009

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on September 18, 2017